Bruker Co. (NASDAQ:BRKR – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the ten research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $81.40.
Several equities research analysts have recently commented on the stock. Citigroup reduced their price target on shares of Bruker from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Wednesday, July 10th. The Goldman Sachs Group reduced their price target on shares of Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a research report on Tuesday, July 9th. TD Cowen reduced their price target on shares of Bruker from $74.00 to $72.00 and set a “hold” rating for the company in a research report on Wednesday, August 7th. Jefferies Financial Group started coverage on shares of Bruker in a research report on Monday, June 3rd. They set a “buy” rating and a $85.00 price target for the company. Finally, Wells Fargo & Company started coverage on shares of Bruker in a report on Tuesday, August 27th. They issued an “overweight” rating and a $78.00 target price for the company.
View Our Latest Report on BRKR
Institutional Investors Weigh In On Bruker
Bruker Price Performance
BRKR opened at $67.25 on Thursday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.75 and a current ratio of 1.65. The stock has a market capitalization of $10.18 billion, a P/E ratio of 24.45, a P/E/G ratio of 2.43 and a beta of 1.18. The company’s 50-day simple moving average is $64.74 and its two-hundred day simple moving average is $72.26. Bruker has a 52-week low of $53.79 and a 52-week high of $94.86.
Bruker (NASDAQ:BRKR – Get Free Report) last posted its earnings results on Tuesday, August 6th. The medical research company reported $0.52 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.52. The business had revenue of $800.70 million for the quarter, compared to analysts’ expectations of $799.44 million. Bruker had a net margin of 11.29% and a return on equity of 24.92%. The business’s revenue for the quarter was up 17.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.50 EPS. As a group, analysts predict that Bruker will post 2.61 EPS for the current year.
Bruker Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Monday, September 2nd were given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.30%. The ex-dividend date of this dividend was Friday, August 30th. Bruker’s payout ratio is currently 7.27%.
About Bruker
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Read More
- Five stocks we like better than Bruker
- About the Markup Calculator
- Should You Invest in Treasury Bills?
- What Does a Stock Split Mean?
- Analysts Think There’s Still Time to Get in on Edgewise, Up 332%
- Options Trading – Understanding Strike Price
- 3 Stocks Raising Dividends 4X Higher Than Inflation
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.